stockrow
Friday 6 November 2026
Export ACXP’s income statement to Excel — free account
Acurx Pharmaceuticals, Inc.
ACXP Healthcare Biotechnology
- EPS
- +72.0%
- Free cash flow
- −2.36%
Quarter to June 2026, against a year earlier
1.07
0.12
+12.63%
Follow ACXP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 5 | 5 | — | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | (6) | (5) | (13) | (12) | (15) | (14) | (8) | (8) | +5.0% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (6) | (5) | (13) | (12) | (15) | (14) | (8) | (8) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (24.71) | (14.86) | (29.80) | (22.40) | (23.00) | (17.40) | (5.32) | (3.10) | (22.6%) | ||||||
| Cash flow | — | — | — | (16.60) | (10.83) | (11.75) | (13.95) | (15.47) | (12.85) | (4.53) | (1.45) | (19.5%) | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (16.60) | (10.83) | (11.75) | (13.95) | (15.47) | (12.85) | (4.53) | (1.45) | (19.5%) | ||||||
| Book value | — | — | — | 3.41 | 8.73 | 29.08 | 13.53 | 7.37 | 0.76 | 3.52 | 1.91 | +0.5% | ||||||
| Shares, m | — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | +35.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (3) | (5) | (8) | (10) | (10) | (7) | (6) | +9.3% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | (4) | (3) | (5) | (8) | (10) | (10) | (7) | (6) | +9.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | 3 | 12 | 7 | 5 | 1 | 5 | 8 | +36.4% | |||||
| Net debt | — | — | — | (2) | (3) | (13) | (9) | (7) | (4) | (8) | (11) | +20.4% | ||||||
| Shareholders’ equity | — | — | — | 1 | 3 | 12 | 7 | 5 | 1 | 5 | 8 | +36.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (468.62) | (159.85) | (154.72) | (106.87) | (170.64) | (243.85) | (137.98) | (87.57) | +330.6 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | (336.86) | (261.25) | (168.71) | (122.61) | (243.33) | (534.03) | (270.80) | (128.11) | +66.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 2 | 3 | 4 | 4 | 4 | 4 | — | +14.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
Acurx Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LGVN Longeveron Inc. | $5.5M | — (loss-making) | — (loss-making) | −9.18% (below 0%: shrinking) | n/m | −49.12% (below 0%: shrinking) | 63.41% | (2,150.17%) | Compare |
| ACXP Acurx Pharmaceuticals, Inc. | $5.3M | — (loss-making) | — | — | n/m | −2.36% (below 0%: shrinking) | — | 0.00% | |
| PCSA Heatwurx Inc. | $5.1M | — (loss-making) | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SNTI Senti Biosciences, Inc. | $5.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| PULM Pulmatrix, Inc. | $5.1M | — (loss-making) | — (loss-making) | −99.86% (below 0%: shrinking) | n/m | +41.26% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CNSY Cerenome, Inc. | $5.1M | — (loss-making) | — (loss-making) | −70.43% (below 0%: shrinking) | n/m | −31.46% (below 0%: shrinking) | 100.00% | (2,203.65%) | Compare |
| IMNN Imunon, Inc. | $5.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | $5.0M | — (loss-making) | — | — | n/m | +57.80% (above 0%: growing) | — | 0.00% | Compare |
| CDIO Cardio Diagnostics Holdings, Inc. | $5.0M | — (loss-making) | — (loss-making) | +23.79% (above 0%: growing) | n/m | +2.59% (above 0%: growing) | 100.00% | (48,193.84%) | Compare |
| Median of peers | $5.1M | — | — | −64.29% | — | −0.82% | 100.00% | (1,075.08%) |
Pay and ownership Proxy statement filed 1 September 2026
Ownership
Directors and executive officers, together
6.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement